SEC Tracker
Get the app

Cartesian Therapeutics RNAC

Cartesian Therapeutics Q2 FY26: revenue $0; diluted EPS $0.46

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Cartesian Therapeutics reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$0−100% from $298K in Q2 FY2510-Q income statement, on EDGAR
  2. Net income$15.8M−1% from $15.9M in Q2 FY2510-Q income statement, on EDGAR
  3. Diluted EPS$0.46−8% from $0.50 in Q2 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$147.6M−8% from $160.3M in Q2 FY2510-Q balance sheet, on EDGAR
  5. Cash from operations−$21.1MAgainst −$17.5M in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Cartesian Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Galectin Therapeutics GALT public float $109M, Jun 30, 2025
  2. Enanta Pharmaceuticals ENTA public float $111M, Mar 31, 2025, over 18 months old
  3. Milestone Pharmaceuticals MIST public float $99M, Jun 30, 2025
  4. DiaMedica Therapeutics DMAC public float $96M, Jun 30, 2025
  5. Larimar Therapeutics LRMR public float $95M, Jun 30, 2025